Get the Stockscreener App
12.55
6.72%
0.79
After Hours:
12.71
0.16
+1.27%
Ginkgo Bioworks Holdings Inc stock is traded at $12.55, with a volume of 1.73M.
It is up +6.72% in the last 24 hours and down -5.99% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
See More
Previous Close:
$11.76
Open:
$11.8
24h Volume:
1.73M
Relative Volume:
1.18
Market Cap:
$590.97M
Revenue:
$217.11M
Net Income/Loss:
$-651.19M
P/E Ratio:
-0.9661
EPS:
-12.99
Net Cash Flow:
$-387.26M
1W Performance:
-4.78%
1M Performance:
-5.99%
6M Performance:
+15.99%
1Y Performance:
+51.20%
1-Day Range:
$11.71
$12.87
1-Week Range:
$10.96
$14.20
52-Week Range:
$5.00
$16.85
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
12.55 | 816.96M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Earnings call transcript: Ginkgo Bioworks Q2 2025 sees stock drop amid EPS miss - Investing.com
Ginkgo's Datapoints Collaborates With Inductive Bio, Tangible Scientific to Make Lab-in-the-Loop Drug Discovery - MarketScreener
Ginkgo Datapoints, Tangible Scientific, and Indictive Bio Partner to Deploy AI-Driven Lab-In-The-Loop Workflows Across the Biopharma Industry - MarketScreener
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry - PR Newswire
Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth - ADVFN Brasil
Ranking Ginkgo Bioworks Holdings Inc. among high performing stocks via tools2025 Price Targets & Smart Money Movement Alerts - Newser
Will Ginkgo Bioworks Holdings Inc. stock go up soonJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser
Detecting price anomalies in Ginkgo Bioworks Holdings Inc. with AIJuly 2025 Earnings & Fast Moving Stock Watchlists - Newser
Is a relief rally coming for Ginkgo Bioworks Holdings Inc. holdersJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - Newser
Is now a turning point for Ginkgo Bioworks Holdings Inc.Wall Street Watch & Risk Managed Trade Strategies - Newser
What to expect from Ginkgo Bioworks Holdings Inc. in the next 30 daysRisk Management & Precise Entry and Exit Recommendations - Newser
Long term hold vs stop loss in Ginkgo Bioworks Holdings Inc.Quarterly Profit Review & Accurate Buy Signal Alerts - Newser
Is Ginkgo Bioworks Holdings Inc. stock reversal real or fake2025 Year in Review & Long-Term Capital Growth Ideas - Newser
Leading vs lagging indicators on Ginkgo Bioworks Holdings Inc. performanceLayoff News & Free Weekly Chart Analysis and Trade Guides - Newser
Ginkgo Bioworks Holdings Inc. stock outlook for YEARWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
What’s next for Ginkgo Bioworks Holdings Inc. stock priceRate Cut & High Accuracy Trade Signal Alerts - Newser
What makes Ginkgo Bioworks Holdings Inc. stock price move sharplySell Signal & Capital Efficiency Focused Ideas - Newser
Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know - MSN
Quant Tools Rank Ginkgo Bioworks Holdings Inc. as High Risk High RewardMarket Sentiment Report & Capital Efficient Trade Techniques - newsimpact.co.kr
Using data models to predict Ginkgo Bioworks Holdings Inc. stock movement2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
Applying Elliott Wave Theory to Ginkgo Bioworks Holdings Inc.Market Trend Summary & Risk Controlled Daily Trade Plans - Newser
Predicting Ginkgo Bioworks Holdings Inc. trend using moving averagesJuly 2025 News Drivers & Free High Accuracy Swing Entry Alerts - Newser
Ginkgo Bioworks Holdings Inc. recovery potential after sell offQuarterly Trade Summary & Real-Time Volume Surge Alerts - Newser
Ginkgo Bioworks Earnings Call: Mixed Sentiment and Strategic Growth - MSN
Is Ginkgo Bioworks Holdings Inc. stock ready for a breakoutVolume Spike & Pattern Based Trade Signal System - Newser
Published on: 2025-08-15 17:28:08 - Newser
Is Ginkgo Bioworks Holdings Inc. stock a falling knife or bargain buy2025 Pullback Review & Weekly Momentum Stock Picks - sundaytimes.kr
How Ginkgo Bioworks Holdings Inc. stock performs during market volatility2025 Trading Recap & Growth Focused Entry Reports - Newser
Ginkgo Bioworks Holdings, Inc. (DNA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Ginkgo Bioworks shares rise 1.21% premarket after appointing Brian O'Sullivan as Head of Commercial for Ginkgo Automation. - AInvest
Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial for External Growth - AInvest
Ginkgo Bioworks Holdings: Mixed Earnings Call with Strategic Growth Potential - AInvest
Ginkgo Bioworks Holdings Reports Q2 2025 Earnings: Revenue Down 12%, Net Loss Narrows by 72% - AInvest
Ginkgo Bioworks Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ginkgo Automation Appoints Brian O'sullivan as Head of Commercial - MarketScreener
Ginkgo Bioworks appoints Brian O’Sullivan as head of commercial By Investing.com - Investing.com Canada
TR | OpenAI4o Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Raises Target Price to $12 - 富途牛牛
Is Ginkgo Bioworks (DNA) a Sell Despite Recent Institutional Buying and Earnings Outages? - AInvest
Ginkgo Bioworks: Assessing the Recent Rally for Potential Value - AInvest
Ginkgo Bioworks: Sell The Recent Rally (NYSE:DNA) - Seeking Alpha
Comparing Ginkgo Bioworks Holdings Inc. in custom built stock radarsFree Swing Trade Entry With Volume Triggers - Newser
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.33 - Yahoo Finance
William Blair Maintains Sell Rating on Ginkgo Bioworks Holdings - AInvest
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2025 Earnings Call Transcript - Insider Monkey
Ginkgo achieves $250M cost-reduction goal early, bolsters financial position - The Business Journals
Ginkgo Bioworks stock price target raised to $16 from $12 at TD Cowen - Investing.com India
Ginkgo Bioworks shares rise 3.01% premarket after achieving $250 million cost reduction goal. - AInvest
Ginkgo Bioworks Q2 2025 Earnings: Revenue Surpasses Estimates, Net Loss Narrows to $60M - AInvest
Ginkgo Bioworks Holdings Inc (DNA) PT Raised to $16 at TD Cowen - StreetInsider
Ginkgo Bioworks Holdings Inc (DNA) Q2 2025 Earnings Call Highlights: Strategic Cost Management ... By GuruFocus - Investing.com Canada
Ginkgo Bioworks Q2 2025 Earnings Call Transcript: Progress Towards Adjusted EBITDA Breakeven and Life Science Tools Expansion - AInvest
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ginkgo Bioworks Holdings Inc Stock (DNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coen Steven P. | See remarks |
Jul 17 '25 |
Sale |
9.84 |
1,084 |
10,669 |
10,679 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):